The Experimental Oncology Group at the National Research Centre (CNIO) in Madrid has recently unveiled findings from genetically engineered mice afflicted with pancreatic ductal adenocarcinoma. The mice "underwent rapid apoptotic cell death that resulted in complete tumour regressions and remained tumour-free for over 200 days post-treatment." While results of these animal studies are promising towards determining therapeutic vulnerabilities of pancreatic cancer, Dr. Ben Westphalen, chair of the European Society of Medical Oncology (ESMO) Precision Oncology Task Force cautions that these results cannot yet be applied to patient care. More work is needed to determine side effects of the triple combination therapy in humans.
Click here to learn more about this news story.
